Expression of Vascular Endothelial Growth Factor in Human Monocyte/Macrophages Stimulated with Lipopolysaccharide

Abstract

SummaryVascular endothelial growth factor (VEGF) is a mitogen for endothelial cells. We have studied the production of VEGF by human macrophages in response to lipopolysaccharide (LPS). Macrophages stimulated with LPS expressed VEGF mRNA and protein in concentration- and time-dependent manners. The LPS-induced expression of VEGF was inhibited by cycloheximide pretreatment, which suggested that synthesis of certain factor(s) is required for the LPS activity. The induction of VEGF was also suppressed by SB203580, an inhibitor of p38 mitogen-activated protein (MAP) kinase. These results suggest that the LPS-induced VEGF expression depends on the p38-mediated expression of c-Jun, which constitutes the AP-1 complex and binds to the AP-1 site in the VEGF promoter. Pretreatment of the cells with dexamethasone did not affect the LPS-induced upregulation of VEGF mRNA but strongly inhibited VEGF protein production, and the involvement of posttranscriptional regulation on VEGF expression by dexamethasone was suggested. The conditioned medium of LPS-stimulated macrophages enhanced the growth of cultured endothelial cells and it was inhibited by an antibody against VEGF. We conclude that macrophages produce VEGF in response to the stimulation with LPS, which may be partly mediated by the p38 MAP kinase pathway.

ESE-1 Is a Novel Transcriptional Mediator of Angiopoietin-1 Expression in the Setting of Inflammation

“…Among these, only binding sites for AP-1 and ETS family members were identified within the Ang-1 promoter. The AP-1 family member c-Jun has been shown to be a critical transcriptional regulator of VEGF gene expression during inflammation and cooperate with the transcription factor HIF-1␣ to regulate the VEGF gene in the setting of hypoxia (38,39).…”

Transcription of the Vascular Endothelial Growth Factor Gene in Macrophages Is Regulated by Liver X Receptors

“…Although resting monocytes and macrophages exhibit a nonangiogenic phenotype under normoxic conditions, hypoxia, elevated lactate levels, and inflammation strongly stimulate VEGF production (18). Treatment with bacterial lipopolysaccharide (LPS) or with CD40L stimulates VEGF production in human primary macrophages (19).…”

Photodynamic therapy combined with systemic corticosteroids for choroidal neovascularisation secondary to punctate inner choroidopathy

“…Spaide 18 proposed a two-component model for CNV consisting of a (a) vascular component comprising vascular endothelial cells, endothelial cell precursors, 20 and inhibiting VEGF production by macrophages 21 Corticosteroids also target the vascular component of CNV by its antiangiogenic effect (downregulation of matrix metalloproteinases). 19 Combination therapy with systemic corticosteroids and PDT is therefore a logical choice in treating CNV owing to PIC.…”